<DOC>
	<DOCNO>NCT00663975</DOCNO>
	<brief_summary>Hypothesis : DCI 1020 capsule safe effective treat exocrine pancreatic insufficiency CF patient &lt; = 2 year age . The result study intend submit FDA part NDA package marketing approval PANCRECARB ( DCI 1020 ) .</brief_summary>
	<brief_title>Open Label Safety Study DCI-1020 Pediatric Cystic Fibrosis ( CF ) Patients</brief_title>
	<detailed_description>A large body data support safety efficacy PANCRECARB® ( pancrelipase ) Capsules available patient age 2 . This study perform gather data demonstrate safety efficacy DCI1020 pediatric CF patient ( ≤ 2 year ) exocrine pancreatic insufficiency . This study also take consideration `` age appropriate '' dose form . Specifically , enzyme administer orally open capsule empty microspheres small amount applesauce example slightly acidic soft food jelly , jello , etc . feeding . The result study intend submit FDA part NDA package marketing approval PANCRECARB® DCI 1020 ( pancrelipase ) .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Pancreatic Diseases</mesh_term>
	<criteria>Male female age ≤ 2 year age Confirmed diagnosis CF base follow criterion : One clinical feature consistent CF phenotype , AND Positive sweat chloride ≥ 60 mEq/liter ( pilocarpine iontophoresis ) , OR Genotype two identifiable mutation consistent CF Adequate nutritional status Pancreatic insufficiency document spot fecal elastase1 ( FE 1 ) great equal 100 micrograms/g stool Clinically stable evidence acute medical condition Parent/Guardian able understand sign write informed consent comply requirement study History fibrosing colonopathy History refractory pancreatic enzyme replacement therapy Solid organ transplant History intraabdominal surgery A current diagnosis history distal intestinal obstruction syndrome ( DIOS ) past six ( 6 ) month , 2 episode DIOS past twelve ( 12 ) month Conditions know increase fecal fat loss include : inflammatory bowel disease , celiac disease , Crohn 's disease , tropical Sprue , Whipple 's disease A know contraindication , sensitivity hypersensitivity porcine pancreatic enzyme Active liver disease liver enzymes ( alanine aminotransferase ( ALT/SGPT ) , aspartate aminotransferase ( AST/SGOT ) bilirubin ≥ 3 time upper limit normal Acute pancreatitis acute exacerbation chronic pancreatitis Antibiotic use follow : Acute treatment systemic ( oral IV ) antibiotic two ( 2 ) week prior screen Treatment erythromycin unwilling discontinue treatment two ( 2 ) week prior screen . ( azithromycin allow ) Change chronic treatment systemic ( oral IV ) antibiotics trial NOTE : Study patient may remain chronic regimen systemic ( oral IV ) antibiotic ( exception erythromycin ) , he/she start antibiotic least 2 week prior study screen , his/her usual bowel pattern time screening , stop change antibiotic study . Receiving enteral tube feed study Breast feeding study ( express breast milk may use , feed breast ) Expected inability cooperate nonadherent require study procedure Use narcotic Poorly control diabetes Participation investigational study drug , biologic , device currently approve marketing , within 30 day screen visit A medical condition investigator deem significant enough interfere ability study patient participate trial interfere assessment effect enzyme therapy fat absorption</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>pancreatic insufficiency</keyword>
	<keyword>pancreatic enzyme</keyword>
	<keyword>pediatrics</keyword>
</DOC>